|
|
News Breaks
|
January 18, 2012
|
| 16:42 EDT |  | CBST |
| theflyonthewall.com: | Cubist announces executive changes | | Effective as of January 20, Santosh Vetticaden will no longer serve as Cubist Pharmaceuticals’s Senior VP, Chief Medical and Development Officer. Steven Gilman, Cubist’s executive VP, Research & Development and Chief Scientific Officer, will assume Vetticaden’s responsibilities during Cubist’s search for Vetticaden’s successor. In accordance with Vetticaden’s retention letter, which is on file with the SEC, Vetticaden will receive severance equal to eighteen months of his current base salary, payable over six months, and will have the right to continue to participate in Cubist’s medical and dental insurance programs for up to eighteen months. :theflyonthewall.com |
|
|
News For CBST From The Last 14 Days Check below for free stories on CBST the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 14, 2012
|
| 16:02 EDT | | CBST |
| theflyonthewall.com: | Cubist announces presentations of data from phase 2 studies of CB-5945 | | Cubist Pharmaceuticals announced that the results from the Phase 2 studies of CB-5945 in patients with chronic non-cancer pain and opioid-induced constipation will be presented at the 31st Annual Scientific Meeting of the American Pain Society taking place May 16 to 19, 2012, in Honolulu and during Digestive Disease Week 2012 taking place May 19 to 22, 2012, in San Diego. Studies 242 and 243 each met the primary endpoint of change from baseline in the number of spontaneous bowel movements over a four-week treatment period. :theflyonthewall.com |
|
|
|
|
|
